• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic launches Envision Pro CGM in Europe

September 17, 2019 By Sean Whooley

Medtronic logo updatedMedtronic (NYSE:MDT) said today that its Envision Pro continuous glucose monitoring system received CE Mark approval and will be commercialized in Europe and the Middle East this fall.

The Envision Pro CGM is designed to provide blinded glucose levels, track events and compile reports for physicians to assess therapies. The CGM collects glucose data to generate up to five diagnostic reports, including the Pattern Snapshot, which is designed to identify patterns of high and low sugar levels and their association with food, medication, exercise and sleep. It does not require finger-stick calibration and communicates wirelessly with the patient’s smartphone.

“Medtronic has a 20-year history in professional CGM as the first company to have an approved physician-use CGM system,” Medtronic VP & GM for non-intensive diabetes therapies Sheri Dodd said in prepared remarks. “The launch of the Envision Pro CGM system represents multiple important innovations as the first disposable and zero calibration CGM from Medtronic.”

“Fingersticks and A1C only show part of how a person’s sugar levels are fluctuating throughout the day,” added Antwerp University Hospital head of endocrinology-diabetology-metabolism Dr. Christophe De Block. “The Envision Pro CGM system will allow me and my patients to see the percent of time that they are in the optimal target glucose range, and when they are high or low, so that we can better uncover how food, exercise and medication affect their sugar levels. This provides me the opportunity to have more informed discussions and to customize the diabetes management plans for my patients, and augments the personal engagement of patients thereby motivating them to adhere to therapeutic advice.”

Yesterday, Medtronic announced a deal with Novo Nordisk to integrate insulin dosing data from Novo Nordisk’s smart insulin pens into Medtronic’s CGM devices.

Shares of MDT were up 0.4% to $109.46 per share in early-morning trading today.

Filed Under: Diabetes, Featured, Regulatory/Compliance Tagged With: Medtronic

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS